Take of the cash and you have about $900 million. Sales for 2014 are pegged at $408 million. Just over 2X sales is still cheap, for SNTS (one could argue for 3-4 times next years sales as being reasonable, which would give us a share price of $20-30). EPS is pegged at $1.22 for 2014. We have maybe some money coming from PAR that is not accounted for and Zegerid back out of the gate with 90% margins, Uceris which will ramp, and Ruconest coming along with RIf MMX and additional indications maybe will come from each one. Everybody should listen to the Cowen presentation, and view the slides. A lot of flavor is added compared to earnings CC.